Trial · NCT05242133
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
NCT05242133, Phase 3, Completed, Cinnagen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis. Trials, record NCT05242133. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05242133
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
- NCT number
- NCT05242133
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 168 participants, actual
- Lead sponsor
- Cinnagen
- Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Interventions
- Pegylated interferon beta-1a, Interferon Beta-1A Prefilled Syringe
- First posted
- 2022-02-16
- Last updated
- 2022-10-18
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Annualized Relapse Rate | 96 weeks | The total number of relapses divided by the total person-time at risk of relapse. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. |
| Secondary | Proportion of patients with 12 weeks of sustained disability progression | Baseline up to week 96 | Clinical evaluation |
| Secondary | Total number of new or newly enlarging T2-hyperintense lesions as detected by brain MRI | Baseline up to week 96 | Sum of the individual number of new or newly enlarging T2-hyperintense lesions at weeks 24, 48, and 96 |
| Secondary | Total number of gadolinium enhancing lesions as detected by brain MRI | Baseline up to week 96 | Sum of the individual number of gadolinium enhancing lesions at weeks 24, 48, and 96 |
| Secondary | Total number of new or newly enlarging T1 hypointense lesions as detected by brain MRI | Baseline up to week 96 | Sum of the individual number new T1 hypointense lesions at weeks 24, 48, and 96 |
| Secondary | Total number of new active lesions as detected by brain MRI | Baseline up to week 96 | Sum of gadolinium enhancing plus non-enhancing new or newly enlarging T2 hyperintense lesions |
| Secondary | Volume of new or newly enlarging T2 hyperintense lesions as detected by brain MRI | Baseline up to week 96 | Inflammatory activity based on MRI measurement of new or newly enlarging T2 lesion volume |
| Secondary | Volume of gadolinium enhancing lesions as detected by brain MRI | Baseline up to week 96 | Inflammatory activity based on MRI measurement of gadolinium enhancing T1 lesion volume |
| Secondary | Volume of new or newly enlarging T1 hypointense lesions as detected by brain MRI | Baseline up to week 96 | Inflammatory activity based on MRI measurement of hypointense T1 lesion volume |
| Secondary | Brain atrophy | Baseline up to week 96 | Percentage of brain volume change from baseline detected by brain MRI |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05242133
GET https://conductscience.org/api/trials/v1/NCT05242133/registered